QQQ   418.20 (-1.23%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
QQQ   418.20 (-1.23%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
QQQ   418.20 (-1.23%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
QQQ   418.20 (-1.23%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
Free Trial
NASDAQ:ADMS

Adamas Pharmaceuticals (ADMS) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)
Free ADMS Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$8.22
▼
$8.22
50-Day Range
$7.97
▼
$8.23
52-Week Range
$4.02
▼
$9.15
Volume
N/A
Average Volume
692,487 shs
Market Capitalization
$376.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ADMS stock logo

About Adamas Pharmaceuticals Stock (NASDAQ:ADMS)

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

ADMS Stock News Headlines

April 7, 2023 | benzinga.com
Survalent, Electroval win bid to provide ICE "first of its kind" ADMS and DERMS platform
April 7, 2023 | marketwatch.com
Advanced Distribution Management Systems (ADMS) Market 2023 | Global Industry Report Forecast 2029
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
March 30, 2023 | marketwatch.com
Advanced Distribution Management Systems (ADMS) Market LATEST REPORT 2023 to 2030
March 3, 2023 | investing.com
Adamas One Corp (JEWL)
March 1, 2023 | marketwatch.com
2023 Advanced Distribution Management System (ADMS) Market: Top Growing Regions for Business Leaders by 2029
March 1, 2023 | marketwatch.com
Advanced Distribution Management System (ADMS) Market 2023 | Global Industry Report Forecast 2029
February 24, 2023 | marketwatch.com
Advanced Distributed Management System (ADMS) Market Is Booming Worldwide Forecast 2023-2029
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
January 14, 2023 | marketwatch.com
Advanced Distribution Management Systems (ADMS) Market Future Trends Demand 2023, and Forecast to 2029
May 25, 2022 | insidermonkey.com
8 Stocks to Buy According to Devesh Gandhi’s SilverArc Capital
November 24, 2021 | finance.yahoo.com
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
November 4, 2021 | finance.yahoo.com
Supernus Pharmaceuticals, inc (SUPN) Q3 2021 Earnings Call Transcript
November 2, 2021 | finance.yahoo.com
How Much Of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Do Institutions Own?
November 1, 2021 | bizjournals.com
East Bay drug maker's potential sale brings lawsuits, job cuts
October 28, 2021 | finance.yahoo.com
Will Adamas Pharmaceuticals (ADMS) Report Negative Q3 Earnings? What You Should Know
October 27, 2021 | finance.yahoo.com
ADAMAS ALERT: Bragar Eagel & Squire, P.C. Announces Commencement of Tender Offer and Encourages Investors to Contact the Firm
October 21, 2021 | finance.yahoo.com
Why Supernus' Acquisition of Adamas Is a Smart Move
October 18, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations
October 18, 2021 | finance.yahoo.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, AZPN, GSKY, GWB; Shareholders are Encouraged to Contact the Firm
October 16, 2021 | prnewswire.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Adamas Pharmaceuticals, Inc. - ADMS
October 15, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Adamas Pharmaceuticals, Inc. - ADMS
October 14, 2021 | finance.yahoo.com
ADAMAS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ADMS and Encourages Investors to Contact the Firm
October 13, 2021 | businesswire.com
ADAMAS PHARMACEUTICALS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas ...
October 12, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Adamas Pharmaceuticals, Inc. Merger
October 12, 2021 | finance.yahoo.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, FLXN, AZPN, CXP; Shareholders are Encouraged to Contact the Firm
October 11, 2021 | businesswire.com
Adamas Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Adamas Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to ...
See More Headlines
Receive ADMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADMS
CUSIP
N/A
CIK
1328143
Web
www.adamaspharma.com
Phone
(510) 450-3500
Fax
510-428-0519
Employees
138
Year Founded
2002

Profitability

EPS (Most Recent Fiscal Year)
($1.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-57,400,000.00
Net Margins
-71.11%
Pretax Margin
-71.11%
Return on Equity
N/A
Return on Assets
-42.96%

Debt

Debt-to-Equity Ratio
21.25
Current Ratio
4.53
Quick Ratio
4.17

Sales & Book Value

Annual Sales
$74.46 million
Price / Sales
5.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.47) per share
Price / Book
-17.49

Miscellaneous

Outstanding Shares
45,787,000
Free Float
37,133,000
Market Cap
$376.37 million
Optionable
Optionable
Beta
2.82

Social Links

7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Key Competitors

View All Competitors

ADMS Stock Analysis - Frequently Asked Questions

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced its earnings results on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.21. The specialty pharmaceutical company had revenue of $25.90 million for the quarter, compared to the consensus estimate of $25.07 million.

What is Neil McFarlane's approval rating as Adamas Pharmaceuticals' CEO?

2 employees have rated Adamas Pharmaceuticals Chief Executive Officer Neil McFarlane on Glassdoor.com. Neil McFarlane has an approval rating of 100% among the company's employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV).

This page (NASDAQ:ADMS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends